Highlights from the trial’s data for this critically ill population include the following:
Survival benefit: There was a 24% reduction in all-cause mortality (primary endpoint of the study) in the leronlimab versus placebo.
Shortened time to recovery: The average length of hospital stay was reduced by 6 days for patients who received leronlimab with ”commonly used COVID-19 treatments,” also referred to as “Standard of Care” or “SoC,” compared to placebo patients who received SoC only, with a statistically significant p-value of 0.005.
Discharge alive: In addition, patients who received leronlimab demonstrated an improved probability of "discharged alive" at Day 28 (28% versus 11%), a 166% better rate than in the placebo group.
What I take away from above is: 125000 deaths could have been avoided, if Leronlimab had been widely available since the beginning of this pandemic.
Survival benefit: There was a 24% reduction in all-cause mortality (primary endpoint of the study) in the leronlimab versus placebo.
Shortened time to recovery: The average length of hospital stay was reduced by 6 days for patients who received leronlimab with ”commonly used COVID-19 treatments,” also referred to as “Standard of Care” or “SoC,” compared to placebo patients who received SoC only, with a statistically significant p-value of 0.005.
Discharge alive: In addition, patients who received leronlimab demonstrated an improved probability of "discharged alive" at Day 28 (28% versus 11%), a 166% better rate than in the placebo group.
What I take away from above is: 125000 deaths could have been avoided, if Leronlimab had been widely available since the beginning of this pandemic.
10
